Genmab went public in October 2000. Genmab is listed on Nasdaq Copenhagen under the symbol GEN and is a member of the OMX Nordic Large Cap Index, the OMX Copenhagen Benchmark Index and the OMX Copenhagen 25 Index (OMXC25). Our ID code/ISIN is DK0010272202. Genmab has also established a sponsored Level 1 American Depositary Receipt (ADR) program, under which Genmab ADRs can be traded on the US over-the-counter (OTC) market under the symbol GMXAY.
Genmab has approximately 75,000 registered shareholders. There are 61,497,571 shares outstanding. Each share has a nominal value of DKK 1, resulting in a share capital of DKK 61,497,571.
Genmab is headquartered in Copenhagen, Denmark, its main research activities are in Utrecht, the Netherlands and Genmab has development and administrative teams in both Copenhagen, Denmark and Princeton, NJ, USA.
Genmab has four subsidiaries: Genmab B.V. and Genmab Holding B.V. in the Netherlands, Genmab US, Inc. in the United States and Genmab K.K. in Japan.
On September 30, 2018 Genmab had 349 full time employees.
Genmab develops antibody therapeutics. Genmab's main focus is on products that can be used to treat cancer, although the company has also developed products for autoimmune disease and CNS indications.
Genmab has two products on the market: DARZALEX® (daratumumab) and Arzerra® (ofatumumab). Read more about these products on our Products in development page.
Yes, Genmab has a number of products in clinical and pre-clinical development. Refer to our product pipeline for more information.
You can find our interim financial reports and annual reports in the Financial reports section of this website.
- Our proprietary DuoBody® technology platform enables us to create human bispecific antibodies that bind to two different targets.
- Genmab’s novel proprietary HexaBody® platform is designed to increase the potency of antibodies. The technology has the potential to enhance antibody therapeutics for a broad range of applications in cancer and infectious diseases.
- Antibody Drug Conjugate (ADC) technology, licensed from other companies, combines antibodies with cytotoxic agents to selectively target tumor cells.
- Antibody generation technology platforms such as the OmniAb® transgenic mouse and rat platforms and the UltiMAb® transgenic mouse technologyare used to create antibodies.
PricewaterhouseCoopers is Genmab's auditor.
You may contact Rachel Gravesen, Senior Vice President, Investor Relations & Communications by phone at +45 3344 7720 or by email
Yes, Genmab has established a sponsored Level 1 ADR program. Click here for more information.